Altimmune stock forecast 2025. As of February 19, 2025, the average one-year price .

Altimmune stock forecast 2025 2 days ago · Explore Altimmune stock price, quotes, charts and forecasts with Benzinga. 72% probability. Most recently the company’s share price was $5. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Altimmune, Inc. 32% from the current stock price of 5. 32: Nov 4, 2024 · GAITHERSBURG, Md. on As far as the long-term Altimmune stock forecast is concerned, here’s what our predictions are currently suggesting: Altimmune stock prediction for 1 year from now: $ 3. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. One equities research Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH. 48 and its 200 day moving average price is $7. 15: $7. Watch ALT chart and read a more detailed Altimmune, Inc. 48 million shares of the Altimmune Inc (NASDAQ:ALT) were traded, and its beta was 0. 76%. During the last trading day the stock fluctuated 12. The 3 days ago · Altimmune Inc has a consensus price target of $22 based on the ratings of 11 analysts. T. 04 . 00K, down -726. Stock Analyst Price Targets - Review. 's (ALT) stock forecast for 2025? Based on our analysis of 12 Wall Street analysts, Altimmune, Inc. Revenue, however, was significantly below expectations at 5 million versus a forecast of 714 million. 77. 48 worth of ALT stock on Feb 2, 2025. 64%) Altimmune's average annual revenue forecast for its fiscal year ending in December 2025 is $3. The analyst firm set a price target for $12. Dec 31, 2021 · Data readouts from multiple clinical trials expected during the next 6 to 12 months. Track more of Altimmune, Inc. 00K in the quarter ending September 30, 2024, a decrease of -98. Return on equity is forecast to be -48. 47%. Nov 8, 2024 · Altimmune is working on a new weight loss drug to improve an a big weakness in the options currently available; lean muscle mass loss. stock last closed at $6. 88 With top-line data expected in Q2 2025, the positive announcement leads to stock rallying, as the drug is expected to reduce liver fat, body weight, and markers of inflammation. The narrower loss was despite revenue slumping from $362,000 to $5,000. financials and stay on top of what is up with the company. March 11, 2025 . 20, this is a gain of 4 High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. 5% per annum. Altimmune management will host a conference call at 8:30 am E. The stock has a market cap of $445. 0, for 2026 Feb. analyst ratings, historical stock prices, earnings estimates & actuals. 67% from the last close, which brings the market valuation of the company to $439. 11. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202 See Altimmune, Inc. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. The company’s 50 day moving average price is $6. 66. 85% on the last trading day (Friday, 14th Mar 2025), rising from $5. Feb 4, 2025 · Institutional investors and hedge funds own 78. 2% in 3 years. future price: according to them, ALT price has a max estimate of 28. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. 00 USD. (ALT) stock quote, history, news and other vital information to help you with your stock trading and investing. 78 on Friday. Share on Twitter Altimmune Stock Mar 3, 2025 · Ratings for Altimmune ALT were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. 96 on Wednesday. 92. 2 days ago · The 6 analysts with 12-month price forecasts for Altimmune stock have an average target of 20. 5 %. Mar 8, 2025 · Altimmune, Inc. 's long-term price predictions for 2024,2025,2026. 28 or -4. 36: 1 month ago: $-0. This comparison reveals trends in analysts' expectations over time. (NASDAQ:ALT) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ETCompany ParticipantsLee Roth - Burns McClellan, Investor Relations 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450 This price target is based on 9 analysts offering 12 month price targets for Altimmune in the last 3 months. 28 and a 12 month high of $14. Stay updated on market trends for ALT. 13 during mid-day trading on Monday, hitting $5. is $0. Strong cash position of $190. See more forecasts. , Feb. Riley 6 days ago · As of March 14, 2025, Altimmune, Inc. stock prices are influenced by market Feb 18, 2025 · Altimmune (NASDAQ:ALT) is approaching a pivotal moment in 2025, one that could redefine its future. 20 to $5. 39 and its 200-day simple moving average is $7. The firm’s 50 day moving average is $6. 32: Feb 4, 2025 · Institutional investors and hedge funds own 78. , Nov. This brings the company's revenue in the last twelve months to $52. 75 and a low estimate of $6. stock was originally listed at a price of $2,100. stock price (ALT), historical data, earnings reports, stock split stock split history, analyst ratings, and forecasts from Perplexity Finance. 1, for 2029 Feb. 77%) Altimmune stock prediction for 2030: $ 3. (ALT) has a median price target of $25. 33 compared to the forecasted -0. 55. 89. (NASDAQ:ALT - Free Report) - Stock analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Monday, March 3rd. (NASDAQ:ALT – Free Report) – Stock analysts at B. 80% rise from the last recorded price of $5. 62%. Get insights on ALT's potential movements and trends with a forecasted value of 9. Stock Forecast Wisdomtree Industrial Metals Enhanced Altimmune Inc Fund Price Forecast for 2025 Jan 8, 2025 · Roger Song has given his Buy rating due to a combination of factors that highlight Altimmune’s promising future prospects. Get the latest Altimmune, Inc. 59. of Feb 27, 2025 · Altimmune (NASDAQ: ALT) Inc. 4 days ago · What is Altimmune's forecast for 2025? According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Altimmune is $20. Altimmune, Inc. HC Mar 11, 2025 · Get a complete stock price history for Altimmune, starting from its first trading day. During the day the stock fluctuated 6. Feb 28, 2024 · Altimmune stock price forecast Copy link to section. 14 Feb 19, 2025 · Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform recommendation. Altimmune has a 12 month low of $5. HC Wainwright analyst P. Feb 20, 2025 · GAITHERSBURG, Md. Prior: P: 220 . 39 and a two-hundred day simple moving average of $7. Analysts have also set a price target for the stock in 2023, further supporting the positive outlook for ALT. Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Altimmune Stock Forecast, ALT stock price prediction. 5% per annum respectively. ALT stock opened at $5. 33% HOLD. 26 per share for the year, down from their prior estimate of $1. The stock price forecast for ALT in 2023 indicates a significant increase compared to its current value. 33% decrease from the reported $20K in 2024. In This Article: (WHO), by 2025, nearly 1 billion Altimmune had revenue of $5. Altimmune Inc Stock (ALT) is expected to reach an average price of $23. And delayed mash p2 trials to end of q2 2025 when alt will have less than 60m The average one-year price target for Altimmune, Inc. Revenue, however, was Mar 3, 2025 · Altimmune, Inc. This indicates a 4 days ago · What is Altimmune, Inc. 00 target price on the stock. comes to $20. 9d ago, source: Seeking Alpha Mar 14, 2025 · GAITHERSBURG, Md. 70 and a 200 day simple moving average of $7. 06% Upside. 79% from a day low at $5. 12 to a high of $29. The forecast for 2026 is $4. 78 See Altimmune, Inc. 9% in 3 years. Mar 14, 2025 · The Altimmune, Inc. 52% from 4098 forecasts. 15/share. 1,440,025 shares of the company traded hands, compared to its average volume of 2,126,872. 33 USD despite the estimation of −0. Sun, Jun 30, 2024, 6:53 AM 5 min read. Altimmune has a one year low of $5. Altimmune Trading Up 3. 9784. 00 USD and a min estimate of 12. 00. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. (ALT) stock, including valuation metrics, financial numbers, share information and more. 3% per annum. 3 million as of December 31, 2021 . (Jun 2025) Current Year (2025) Next Year (2026) No. ’s stock price is $5. Detailed statistics for Altimmune, Inc. The forecasts range from a low of $10. AAII advises against making stock decisions based solely on price or past returns. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. As of 31 March, 2024, the company experienced a revenue decline of approximately -76. 31% year over year. (Mar 2025) Next Qtr. 03 (-0. Altimmune Fund Price Forecast, ALT fund price prediction. Forecast for 2025 Mar. Shares of ALT opened at $6. Altimmune Stock Performance. 920, which is up 13. 6 % Shares of ALT traded down $0. Mar 20, 2025, 8:30 AM EDT. The average target predicts an increase of 275. 35 and its 200 day moving average is $7. 3 Equities analysts who give forecasts on ALT, They sold $54,992. Mar 14, 2025 · GAITHERSBURG, Md. 83: Friday, 7th Feb 2025 ALT stock ended at $6. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. 2025 which is in 54 days. 32 in 2024. is $3. 00K, down -81. And delayed mash p2 trials to end of q2 2025 when alt will have less than 60m On Friday morning 03/14/2025 the Altimmune Inc Registered Shs share started trading at the price of $5. 30. Oct 27, 2021 · From AI system, total return is 2366. 67% BUY and 8. on March 18, 2025. 75M. If you had invested in Altimmune stock at $2,100. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune stock traded up $0. 33 USD. ALT stock quote prices, financial information, real-time forecasts, and company news from CNN. and suggest that you do with its stocks. is $22. 44 on Friday. The average price target is $20. WHAT'S NEXT Altimmune plans to initiate a mid-stage trial testing pemvidutide for alcohol use disorder in the second quarter and another High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. (ALT) stock price prediction for the next 5 days on 13 Feb 2025 5-Day prediction shows that the price will grow by 0% probability and have a downward trend by 6. 1 days. 22M for 2027, and $469M for 2028. 1,735,127 shares of the stock traded hands, compared to its average volume of 3,001,317. 00 to a high of $28. EPS is expected to grow by 37. com Staff Jun 30, 2023 · About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. 6 analysts have given Altimmune (ALT) a consensus rating of Buy while the Altimmune (ALT) price prediction in 2025 is $7. 83, with a low estimate of 12 and a high estimate of 26. This is 1,087. I believe Altimmune offers a compelling risk-reward profile, and as such, I am long the stock Jun 21, 2024 · Revenue Growth: Altimmune's revenue growth over a period of 3 months has faced challenges. 82%) Altimmune stock forecast for 2025: $ 4. 17. 1 day ago · ALT opened at $5. Price target in 14 days: 5. Coinbase to re-enter India as it registers with the FIU . Return on equity is forecast to be -39. 29. Dec 16, 2024 · If Altimmune signs a strategic partner in 2025, potential FDA approval will be in 2028, including availability of off-label use in USA If Altimmune signs a strategic partner, the partner will take Jun 30, 2024 · 3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics. Analysts average stock forecasts to be materialized ratio is 12. The average analyst rating for Altimmune stock from 8 stock analysts is "Strong Buy". A key factor is the upcoming 24-week biopsy data readout for their lead Mar 6, 2025 · Read Altimmune FY2029 EPS Forecast Decreased by HC Wainwright at Defense World HC Wainwright currently has a “Buy” rating and a $12. 6% and 84. Altimmune Inc lowest stock price was $5. 98% with an average time for these price targets to be met of 35. 45. stock forecast: see what analysts think of Altimmune, Inc. Dec 30, 2024 · Back in October, I rated Altimmune (NASDAQ:ALT) a hold, based on the fact that while I liked the prospects of ALT's incretin drug, pemvidutide, I wanted to hear the outcome of the company's end-of We've gathered analysts' opinions on Altimmune, Inc. 05 (-45. 07 percentage points lower than the US Biotechnology industry revenue growth rate of 991. , March 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. The consensus estimate for . 92 on Friday. 34. stock price gained 13. During Altimmune’s recent R&D Day Mar 6, 2025 · GAITHERSBURG, M. New 20 hours ago · Altimmune Trading Down 0. 14 and its highest was $11. 78 -0. Altimmune's revenue in the past year totaled $20. 71, and it changed around -$0. 56. 2025. 2 days ago · Get Our Latest Stock Report on ALT. , March 15, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. 7% and 64. 7493. 14 and a one year high of Mar 3, 2025 · Altimmune Stock Performance. Mar 9, 2025 · Research Altimmune's (Nasdaq:ALT) stock price, latest news & stock analysis. The table below provides a snapshot of their recent ratings Mar 3, 2025 · Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Altimmune's stock. The average price target represents a 258. Mar 14, 2025 · Based on short-term price targets offered by nine analysts, the average price target for Altimmune, Inc. 36% year-over-year. Altimmune has a fifty-two week low of $5. Altimmune 2025: Redefining Obesity And MASH Treatment Consensus forecasts updated 3 days ago · The latest price target for Altimmune (NASDAQ:ALT) was reported by HC Wainwright & Co. 83, with a high forecast of $26. 81 on Tuesday. 867 USD. Jun 1, 2020 · The stock rating distribution of ALT is 91. They Mar 13, 2025 · The Danish drugmaker is also testing semaglutide - sold as the diabetes drug Ozempic and the obesity drug Wegovy - in thousands of patients with early-stage Alzheimer's disease, with results expected in 2025. (ALT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Riley increased their FY2025 earnings estimates for Altimmune in a research note issued on Friday, February 28th. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will host a virtual R&D Day on Thursday, March 13, 2025 beginning at 12:00 pm Eastern Time. 00 in Oct 6, 2005. 06, for 2030 Feb. ALT chart by TradingView. Minimizing the loss of lean muscle mass could provide a large benefit to an important segment of GLP-1 users. Alex Carchidi, The Motley Fool . 4 days ago · What is Altimmune, Inc. Analyst Price Forecast Suggests 232. 00, your return over the last 19 years would have been -99. GAITHERSBURG, Md. As of February 19, 2025, the average one-year price As of Q1 2025, Altimmune's revenue has grown -95. 28 and a 1 year high of $11. 6 days ago · Other equities analysts also recently issued reports about the stock. 00 and the lowest is $12. reported its fourth-quarter 2024 earnings, revealing a slight beat on EPS forecasts with an actual EPS of -0. Q2 2025 Estimate Trends; Current: $-0. 58% upside from the last price of $5. (NASDAQ:ALT – Free Report) – Stock analysts at HC Wainwright cut their Q2 2025 earnings estimates for shares of Altimmune in a report released on Monday, March 3rd. 6 days ago · ALT stock opened at $5. The highest price target is $28. 00 thousand. Nov 19, 2024 · Stay updated on Altimmune, Inc. 84. 72%, for an annualized return of -26. B. 12K, followed by $55. 69. . 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. Mar 9, 2025 · Altimmune, Inc. 14 Feb 4, 2025 · Altimmune Stock Down 3. is $6. 28% (The price fluctuation will be experienced). Make informed decisions in the Equity market. The low is $12 issued by HC Wainwright & Co. The business’s 50-day simple moving average is $6. 39 in 2023 to $0. 88 (-30. 09. The best long-term & short-term Altimmune share price prognosis for 2023 Feb 27, 2025 · Altimmune (NASDAQ:ALT) Inc. HC Wainwright reaffirmed a "buy" rating and set a $12. View Altimmune, Inc. The high is $35 issued by Jefferies on August 31, 2022. 2 Feb 14, 2025 · Altimmune. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. 40. 58% (not including any dividends or dividend reinvestments). 65 to a Mar 7, 2025 · HC Wainwright analyst P. 78. 02, and for 2034 Feb. Mar 13, 2025 · About ALT. 38 USD. Includes open, high, low, close and volume. Mar 3, 2025 · Altimmune is forecast to grow earnings and revenue by 27. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a Gaithersburg, Maryland-based Altimmune reported a third-quarter net loss that narrowed from $0. Mar 14, 2025 · Is Altimmune Stock a good buy in 2025, according to Wall Street analysts? The consensus among 4 Wall Street analysts covering (NASDAQ: ALT) stock is to Strong Buy ALT stock. In the year 2023, Altimmune had annual revenue of $426. Altimmune's drug has shown better lean muscle mass loss compared to Eli Lilly and Novo Nordisk's drugs. With these forecasts and analyst ratings, it is evident that ALT stock is considered a good buy by many investors. Feb 20, 2025 · Altimmune, Inc. Compared to the closing price on Thursday 03/13/2025 on BTT of $5. 18% less than the trading day before Thursday, 6th Feb 2025. Feb 7, 2025 · Range Low Price High Price Comment; 30 days: $6. Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. is $1. In the next quarter EPS is expected to reach −0. 28 (-23. 75 in 2025, with a high prediction of $40. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. . D. 85% from its previous closing price. The company’s 50 day moving average price is $7 Find the latest Altimmune, Inc. EPS is expected to grow by 28. 14 and a fifty-two Mar 14, 2025 · Altimmune. 05% of the company’s stock. 37, Out of . This is 3. 20, this is a gain of 4 910 Clopper Road Suite 201-S Gaithersburg, MD 20878 (240) 654-1450 Mar 14, 2025 · According to InvestingPro data, analyst targets for the stock range from $12 to $28, suggesting significant upside potential from the current price of $5. Mar 5, 2025 · Altimmune Trading Down 0. 16 in the past 12 months. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202 4 days ago · → A brutally honest economic warning for 2025 (see proof) (From Banyan Hill Publishing) (Ad) Free ALT Stock Alerts Altimmune (ALT) Stock Chart & Stock Price History $5. 6 %. 33K, reflecting a -83. Dec 11, 2024 · Altimmune is forecast to grow earnings and revenue by 18. The company has a 50-day simple moving average of $6. Trucchio now forecasts that the company will earn $1. 20 during midday trading on Tuesday, reaching $5. This page was last updated on 03/16/2025 by Financhill. (ALT) price has no a definite trend is 93. This indicates an +308. 81. Shares of ALT stock opened at $5. 00 target price on shares of Altimmune in a research note on Monday, March 3rd. The company’s 50 day moving average is $6. 09% from a day low at $6. 19%. on February 27 to discuss Altimmune Inc. The forecasts range from a low of $12. 00 expecting ALT to rise to within 12 months On Friday morning 03/14/2025 the Altimmune Inc Registered Shs share started trading at the price of $5. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. 25 during trading hours on Friday, reaching $6. 2,990,173 shares of the stock were exchanged, compared to its average volume of 2,312,039. * Altimmune stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences. Shares of Altimmune stock traded down $0. 9% per annum respectively. Nov 12, 2024 · Altimmune, Inc. ALT updated stock price target summary. 00 and a low forecast of $12. has a 1 year low of $5. ALT Stock 12 Month Forecast. March 11, 2025 May 12, 2017 · Altimmune, Inc. ALT EPS for the last quarter is −0. 52%) Feb 20, 2025 · GAITHERSBURG, Md. As of February 19, 2025, the average one-year price target for Altimmune is $22. 98. 36 to a day high of $6. Mar 4, 2025 · In the last trading session, 0. Moreover, the probability that Altimmune, Inc. kyeqwfh dosd bcdux vio fhqxmc efwfe btizwk xfm kydr svu yeigmo erepba okstv iyp vkuug